Tokyo, Japan

Takuya Tokuda

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2021-2024

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Takuya Tokuda: Innovator in Ophthalmic Therapeutics

Introduction

Takuya Tokuda is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of ophthalmic therapeutics, focusing on innovative pharmaceutical compositions. With a total of 2 patents to his name, Tokuda is recognized for his groundbreaking work in developing therapeutic agents for eye diseases.

Latest Patents

Tokuda's latest patents include a pharmaceutical composition that relates to a therapeutic agent for ophthalmic diseases. This invention comprises a vascular endothelial growth factor (VEGF) receptor inhibitor or an epidermal growth factor (EGF) receptor inhibitor in a nanoparticle form. The unique property of this composition allows it to be retained in the posterior eye tissue when systemically administered, showcasing Tokuda's commitment to advancing medical treatments.

Career Highlights

Throughout his career, Takuya Tokuda has been associated with Kyowa Kirin Co., Ltd., a leading company in the pharmaceutical industry. His work has not only contributed to the company's innovative portfolio but has also positioned him as a key figure in the development of new therapeutic solutions for ophthalmic conditions.

Collaborations

Tokuda has collaborated with notable colleagues, including Hiroki Haniuda and Sachiko Enokizono. These partnerships have fostered a collaborative environment that enhances the research and development of effective pharmaceutical compositions.

Conclusion

Takuya Tokuda's contributions to ophthalmic therapeutics through his innovative patents and collaborations highlight his role as a significant inventor in the field. His work continues to pave the way for advancements in medical treatments for eye diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…